This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.93% per year. These returns cover a period from January 1, 1988 through October 6, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Theravance's Q4 Loss In Line With Estimates, Sales Beat
by Zacks Equity Research
TBPH's fourth-quarter earnings match estimates while sales beat the same marginally. Increased collaboration revenues from Viatris drive revenues higher.
Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Why This 1 Value Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Should You Buy, Hold or Sell Moderna Stock Post Q4 Earnings Release?
by Sundeep Ganoria
Given the uncertainty around its revenue growth, we advise short-term investors to remain cautious when investing in MRNA stock.
Gilead Stock Rises 8% Post Q4 Earnings: Should You Buy or Sell?
by Ekta Bagri
GILD's strong HIV portfolio should maintain momentum for the company. The guidance for 2025 is impressive. We believe there is more room for growth and recommend the stock to investors.
Moderna Q4 Earnings and Revenues Beat, COVID Vaccine Sales Decline
by Zacks Equity Research
MRNA's earnings and revenues surpass estimates in the fourth quarter of 2024. The company reiterates 2025 total revenue guidance.
GILD Stock Up on Q4 Earnings and Sales Beat & Upbeat '25 Guidance
by Zacks Equity Research
Gilead Sciences' Q4 earnings and sales beat estimates on higher HIV, oncology and liver disease drug sales. The stock is trading up.
Bear Of The Day: GSK PLC (GSK)
by Brian Bolan
Healthcare stock investors have been feeling rather sick about the potential changes the Trump Administration may bring.
Kratos Defense and GSK have been highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Kratos Defense and GSK have been highlighted as Zacks Bull and Bear of the Day.
GSK Beats on Q4 Earnings & Sales, Stock Up on Raised Long-Term Outlook
by Zacks Equity Research
GSK reports better-than-expected Q4 earnings. It also announces a new share buyback program and raises the long-term sales outlook for 2031 by $2 billion.
GSK (GSK) Tops Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Glaxo (GSK) delivered earnings and revenue surprises of 11.32% and 4.04%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Illumina (ILMN) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Illumina (ILMN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Earnings Preview: GSK (GSK) Q4 Earnings Expected to Decline
by Zacks Equity Research
Glaxo (GSK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
EMA Accepts GSK's Filing for Depemokimab in Two Respiratory Diseases
by Zacks Equity Research
If approved, GSK's depemokimab will be the first ultra-long-acting biologic that requires only one dose every six months.
New Strong Sell Stocks for January 23rd
by Zacks Equity Research
ARCO, CAG and GSK have been added to the Zacks Rank #5 (Strong Sell) List on January 23, 2025.
GSK's Jemperli Gets EU Nod for Expanded Use in Endometrial Cancer
by Zacks Equity Research
The European Commission approves GSK's Jemperli plus chemotherapy to treat all adult patients with primary, advanced or recurrent endometrial cancer.
Incyte Gains 15.3% in a Year: Is There Room for Further Growth?
by Zacks Equity Research
INCY has delivered a good performance in the past year on positive data readouts and encouraging pipeline progress. We believe there is room for further growth at current levels.
Can Gilead Sciences Sustain Its Growth Momentum in 2025?
by Ekta Bagri
GILD has performed well in the past six months, with new drug approvals, positive data readouts and strong quarterly results. While the fundamentals look solid, we advise investors to remain on the sidelines at current levels.
How to Play Moderna Stock After the Recent Sales Guidance Cut
by Sundeep Ganoria
Given the uncertainty regarding its top-line growth, we would advise short-term investors to steer clear of MRNA stock.
The Zacks Analyst Blog Moderna, Regeneron, Intellia Sage and GSK
by Zacks Equity Research
Moderna, Regeneron, Intellia Sage and GSK are included in this Analyst Blog.
Biotech Stock Roundup: MRNA, NTLA Down on Updates, SAGE Up on Biogen's Offer & Other Updates
by Zacks Equity Research
MRNA and NTLA are down this week after providing financial and strategic updates.
The Zacks Analyst Blog Highlights J&J, Eli Lilly, GSK and Intra-Cellular
by Zacks Equity Research
J&J, Eli Lilly, GSK and Intra-Cellular are included in this Analyst Blog.
JNJ, GSK, LLY Announce M&A Deals at JP Morgan Conference
by Kinjel Shah
J&J announces a big deal to acquire neuroscience company ITCI for $14.6 billion, while Lilly and GSK announce smaller deals.
Pharma Stock Roundup: FDA Updates for JNJ, GSK, PFE, NVO's Expanded Deal
by Kinjel Shah
FDA grants priority review tag to JNJ's nipocalimab BLA for gMG and asks for new warnings on GSK & PFE's RSV vaccine labels.
GSK's ADC Drug Gets FDA's Breakthrough Tag for Rare Bone Cancer
by Zacks Equity Research
The FDA bestows a Breakthrough Therapy designation to GSK's antibody-drug conjugate, GSK5764227, for treating relapsed or refractory osteosarcoma.